ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Astellas Pharma, AstraZeneca and Bristol-Myers Squibb side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

Astellas Pharma×AstraZeneca×Bristol-Myers Squibb×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Astellas PharmaAstraZenecaBristol-Myers Squibb
studies on the registry9834,1972,184
open to participants now38298155
phase 3 studies under way1320082
reach primary completion within a year1416867
programswith a study of their own in two years20119+5 named only57+9 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseAstellas PharmaAstraZenecaBristol-Myers Squibb
Phase 1

Astellas Pharma: 2 of its 20 programs at phase 1

  1. ASP2020phase 1
  2. Pan-KRAS Degrader ASP5834phase 1
10%

AstraZeneca: 25 of its 119 programs at phase 1

  1. AZD4954phase 1
  2. AZD1613phase 1
  3. AZD1390phase 1
  4. Actinium Ac 225-DOTA-Anti-STEAP2 Monoclonal Antibody AZD2284phase 1
  5. ALXN2230phase 1

and 20 more — sign in to see them all

21%

Bristol-Myers Squibb: 17 of its 57 programs at phase 1

  1. BMS-986454phase 1
  2. orevandrodegphase 1
  3. Actinium Ac 225 SSTR2-targeted Agent RYZ401phase 1
  4. BMS-985521phase 1
  5. BMS-986485phase 1

and 12 more — sign in to see them all

30%
Phase 245%

AstraZeneca: 47 of its 119 programs at phase 2

  1. AZD9550phase 2
  2. zadavotide guraxetanphase 2
  3. palacaparibphase 2
  4. Berzanoflastphase 2
  5. AZD7798phase 2

and 42 more — sign in to see them all

39%

Bristol-Myers Squibb: 17 of its 57 programs at phase 2

  1. irafamdastatphase 2
  2. moponetugphase 2
  3. delocamtenphase 2
  4. imzokitugphase 2
  5. Cyclophosphamidephase 2

and 12 more — sign in to see them all

30%
Phase 3

Astellas Pharma: 4 of its 20 programs at phase 3

  1. fezolinetantphase 3
  2. setidegrasibphase 3
  3. emaretamigphase 3
  4. gilteritinibphase 3
20%

AstraZeneca: 28 of its 119 programs at phase 3

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. tremelimumabphase 3
  4. volrustomigphase 3
  5. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3

and 23 more — sign in to see them all

24%

Bristol-Myers Squibb: 16 of its 57 programs at phase 3

  1. navlimetostatphase 3
  2. pumitamigphase 3
  3. adagrasibphase 3
  4. golcadomidephase 3
  5. zolacabtagene autoleucelphase 3

and 11 more — sign in to see them all

28%
Approved, new studies

Astellas Pharma: 5 of its 20 programs at approved, new studies

  1. zolbetuximabapproved, new study
  2. enfortumab vedotinapproved, new study
  3. enzalutamideapproved, new study
  4. avacincaptad pegolapproved, new study
  5. Sirolimusapproved, new study
25%

AstraZeneca: 19 of its 119 programs at approved, new studies

  1. durvalumabapproved, new study
  2. acalabrutinibapproved, new study
  3. trastuzumab deruxtecanapproved, new study
  4. osimertinibapproved, new study
  5. anifrolumabapproved, new study

and 14 more — sign in to see them all

16%

Bristol-Myers Squibb: 7 of its 57 programs at approved, new studies

  1. xanomelineapproved, new study
  2. trospiumapproved, new study
  3. deucravacitinibapproved, new study
  4. Nivolumabapproved, new study
  5. trospium chlorideapproved, new study

and 2 more — sign in to see them all

12%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Astellas Pharma9 readouts · 2 phase 3·

Astellas Pharma, Dec ’26: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. Anti-Claudin 18.2 Antibody-drug Conjugate ASP546Cphase 2 · Dec 30 · NCT06792435
  2. enfortumab vedotinapproved, new study · Dec 31 · NCT06862219
  3. zolbetuximabapproved, new study · Dec 31 · NCT06396091
···

Astellas Pharma, Apr ’27: 2 programs whose next study reaches primary completion

  1. enzalutamideapproved, new study · Apr 30 · NCT07783282
  2. fezolinetantphase 3 · Apr 30 · NCT07783282
·

Astellas Pharma, Jun ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. avacincaptad pegolapproved, new study · Jun 30 · NCT06970665
···

Astellas Pharma, Oct ’27: 3 programs whose next study reaches primary completion

  1. Methylprednisolonephase 2 · Oct 31 · NCT07052929
  2. Prednisolonephase 2 · Oct 31 · NCT07052929
  3. Sirolimusapproved, new study · Oct 31 · NCT07052929
AstraZeneca60 readouts · 16 phase 3

AstraZeneca, Nov ’26: 4 programs whose next study reaches primary completion

  1. Autologous dnTGF-BRII-armored Anti-STEAP2 CAR T-cells AZD0754phase 2 · Nov 24 · NCT06267729
  2. STEAP2-targeting Radioconjugate AZD2287phase 2 · Nov 24 · NCT06267729
  3. durvalumabapproved, new study · Nov 30 · NCT07081633
  4. tremelimumabphase 3 · Nov 30 · NCT07081633

AstraZeneca, Dec ’26: 7 programs whose next study reaches primary completion, 2 in phase 3

  1. eculizumabapproved, new study · Dec 7 · NCT06724809
  2. AZD3974phase 1 · Dec 8 · NCT07290283
  3. baxdrostatphase 3 · Dec 10 · NCT07222917
  4. dapagliflozinapproved, new study · Dec 10 · NCT07222917
  5. benralizumabapproved, new study · Dec 23 · NCT05692180

and 2 more — sign in to see them all

AstraZeneca, Jan ’27: 13 programs whose next study reaches primary completion, 6 in phase 3

  1. laroprovstatphase 3 · Jan 4 · NCT07000136
  2. anifrolumabapproved, new study · Jan 6 · NCT05925803
  3. monalizumabphase 3 · Jan 8 · NCT05221840
  4. oleclumabphase 3 · Jan 8 · NCT05221840
  5. datopotamab deruxtecanphase 3 · Jan 11 · NCT06417814

and 8 more — sign in to see them all

AstraZeneca, Feb ’27: 7 programs whose next study reaches primary completion, 3 in phase 3

  1. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3 · Feb 1 · NCT06530849
  2. trastuzumab deruxtecanapproved, new study · Feb 10 · NCT06271837
  3. Berzanoflastphase 2 · Feb 11 · NCT07215702
  4. acalabrutinibapproved, new study · Feb 15 · NCT02972840
  5. zibotentanphase 3 · Feb 18 · NCT06087835

and 2 more — sign in to see them all

AstraZeneca, Mar ’27: 4 programs whose next study reaches primary completion

  1. AZD7760phase 2 · Mar 8 · NCT06749457
  2. AZD4954phase 1 · Mar 17 · NCT07812077
  3. AZD0543phase 1 · Mar 24 · NCT07824622
  4. Anti-Claudin 18.2 Antibody-drug Conjugate AZD4360phase 2 · Mar 31 · NCT06921928

AstraZeneca, Apr ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. AZD1043phase 1 · Apr 9 · NCT07511205
  2. camizestrantphase 3 · Apr 20 · NCT05774951
  3. ombetoxabartphase 2 · Apr 20 · NCT07285213

AstraZeneca, May ’27: 5 programs whose next study reaches primary completion, 2 in phase 3

  1. rilvegostomigphase 3 · May 4 · NCT04379596
  2. Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492phase 2 · May 5 · NCT06916806
  3. AZD1613phase 1 · May 22 · NCT07228364
  4. Budesonideapproved, new study · May 31 · NCT07073950
  5. formoterolapproved, new study · May 31 · NCT07073950

AstraZeneca, Jun ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. tozorakimabphase 3 · Jun 7 · NCT06932263
  2. ravulizumabapproved, new study · Jun 25 · NCT07308574
  3. Anti-GPC3 T Cell-engaging Antibody AZD9793phase 2 · Jun 30 · NCT06795022

AstraZeneca, Jul ’27: 3 programs whose next study reaches primary completion

  1. ALXN1920phase 2 · Jul 2 · NCT07157787
  2. AZD2389phase 2 · Jul 7 · NCT07610837
  3. SC rilvegostomig + rHuphase 1 · Jul 19 · NCT07161414

AstraZeneca, Aug ’27: 4 programs whose next study reaches primary completion

  1. ALXN2230phase 1 · Aug 9 · NCT07352423
  2. AZD0240phase 1 · Aug 30 · NCT06218914
  3. SC durvalumab + rHuphase 1 · Aug 30 · NCT07391670
  4. AZD6793phase 2 · Aug 31 · NCT07082738

AstraZeneca, Sep ’27: 2 programs whose next study reaches primary completion

  1. palacaparibphase 2 · Sep 29 · NCT05123482
  2. puxitatug samrotecanphase 3 · Sep 29 · NCT05123482

AstraZeneca, Oct ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. opemalirsenphase 2 · Oct 4 · NCT06824987
  2. cevolisiranphase 2 · Oct 11 · NCT06744647
  3. tarperprumigphase 2 · Oct 11 · NCT07160608
  4. torvutatug samrotecanphase 3 · Oct 15 · NCT07402915
  5. sodium zirconium cyclosilicateapproved, new study · Oct 30 · NCT07944378
Bristol-Myers Squibb22 readouts · 7 phase 3

Bristol-Myers Squibb, Nov ’26: 2 programs whose next study reaches primary completion, 2 in phase 3

  1. trospiumapproved, new study · Nov 24 · NCT06585787
  2. xanomelineapproved, new study · Nov 24 · NCT06585787

Bristol-Myers Squibb, Dec ’26: 7 programs whose next study reaches primary completion, 1 in phase 3

  1. actinium AC-225 dotatatephase 3 · Dec 0 · NCT05477576
  2. navlimetostatphase 3 · Dec 5 · NCT07777133
  3. delocamtenphase 2 · Dec 14 · NCT06122779
  4. golcadomidephase 3 · Dec 14 · NCT07763418
  5. moponetugphase 2 · Dec 17 · NCT06268886

and 2 more — sign in to see them all

Bristol-Myers Squibb, Jan ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. mezigdomidephase 3 · Jan 10 · NCT05519085

Bristol-Myers Squibb, Feb ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. Actinium Ac 225 SSTR2-targeted Agent RYZ401phase 1 · Feb 0 · NCT07165132
  2. Nivolumabapproved, new study · Feb 5 · NCT06946797
  3. repotrectinibphase 3 · Feb 16 · NCT06140836

Bristol-Myers Squibb, Mar ’27: 1 program whose next study reaches primary completion

  1. trospium chlorideapproved, new study · Mar 29 · NCT07063342
·

Bristol-Myers Squibb, May ’27: 1 program whose next study reaches primary completion

  1. elranatamabphase 2 · May 31 · NCT06988488

Bristol-Myers Squibb, Jun ’27: 3 programs whose next study reaches primary completion

  1. BMS-986533phase 1 · Jun 1 · NCT07629999
  2. BMS-986485phase 1 · Jun 8 · NCT07887763
  3. BMS-986454phase 1 · Jun 28 · NCT07171983

Bristol-Myers Squibb, Jul ’27: 1 program whose next study reaches primary completion

  1. zolacabtagene autoleucelphase 3 · Jul 15 · NCT06220201

Bristol-Myers Squibb, Aug ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. atigotatugphase 3 · Aug 17 · NCT06646276

Bristol-Myers Squibb, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. dezandrodegphase 3 · Sep 12 · NCT06764485

Bristol-Myers Squibb, Oct ’27: 1 program whose next study reaches primary completion

  1. BMS-986488phase 1 · Oct 15 · NCT06764771
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 23, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Astellas Pharma

New programs 1

  • ASP2957phase 2 · first study · Oct 9 · Myopathies, Structural, Congenital

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 1

AstraZeneca

New programs 2

Reached a new phase 1

Study stopped 0

None

Primary completion later 23

Bristol-Myers Squibb

New programs 5

  • BMS-986548phase 2 · first study · Nov 10
  • BMS-986485phase 1 · first study · Oct 14
  • BMS-986553phase 1 · first study · Oct 8 · Lupus Nephritis
  • RYZ711phase 2 · first study · Oct 1 · Prostatic Neoplasms
  • BMS-986527phase 1 · first study · Sep 22 · Carcinoma, Renal Cell

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 42 in all, the first 12 here. A program counts in each condition its studies name most.

ConditionAstellas PharmaAstraZenecaBristol-Myers Squibb
Carcinoma, Non-Small-Cell Lungall three · compare here

Astellas Pharma in Carcinoma, Non-Small-Cell Lung: 3 programs

  1. setidegrasibphase 3
  2. gilteritinibphase 3
  3. Pan-KRAS Degrader ASP5834phase 1

Their studies: Astellas Pharma’s studies of Carcinoma, Non-Small-Cell Lung in search

AstraZeneca in Carcinoma, Non-Small-Cell Lung: 16 programs

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. tremelimumabphase 3
  4. volrustomigphase 3
  5. ceralasertibphase 3

and 11 more — sign in to see them all

Their studies: AstraZeneca’s studies of Carcinoma, Non-Small-Cell Lung in search

Bristol-Myers Squibb in Carcinoma, Non-Small-Cell Lung: 11 programs

  1. navlimetostatphase 3
  2. pumitamigphase 3
  3. adagrasibphase 3
  4. izalontamab brengitecanphase 3
  5. repotrectinibphase 3

and 6 more — sign in to see them all

Their studies: Bristol-Myers Squibb’s studies of Carcinoma, Non-Small-Cell Lung in search

Prostatic Neoplasmsall three · compare here

Astellas Pharma in Prostatic Neoplasms: 4 programs

  1. fezolinetantphase 3
  2. Prednisolonephase 2
  3. ASP5541phase 2
  4. enzalutamideapproved, new study

Their studies: Astellas Pharma’s studies of Prostatic Neoplasms in search

AstraZeneca in Prostatic Neoplasms: 13 programs

  1. saruparibphase 3
  2. capivasertibphase 3
  3. zibotentanphase 3
  4. Actinium-225phase 3
  5. zadavotide guraxetanphase 2

and 8 more — sign in to see them all

Their studies: AstraZeneca’s studies of Prostatic Neoplasms in search

Bristol-Myers Squibb in Prostatic Neoplasms: 3 programs

  1. dezandrodegphase 3
  2. RYZ711phase 2
  3. orevandrodegphase 1

Their studies: Bristol-Myers Squibb’s studies of Prostatic Neoplasms in search

Breast Neoplasmsall three · compare here

Astellas Pharma in Breast Neoplasms: 2 programs

  1. enzalutamideapproved, new study
  2. Sirolimusapproved, new study

Their studies: Astellas Pharma’s studies of Breast Neoplasms in search

AstraZeneca in Breast Neoplasms: 10 programs

  1. datopotamab deruxtecanphase 3
  2. saruparibphase 3
  3. capivasertibphase 3
  4. camizestrantphase 3
  5. puxitatug samrotecanphase 3

and 5 more — sign in to see them all

Their studies: AstraZeneca’s studies of Breast Neoplasms in search

Bristol-Myers Squibb in Breast Neoplasms: 4 programs

  1. pumitamigphase 3
  2. izalontamab brengitecanphase 3
  3. actinium AC-225 dotatatephase 3
  4. Cyclophosphamidephase 2

Their studies: Bristol-Myers Squibb’s studies of Breast Neoplasms in search

Neoplasmsall three · compare here

Astellas Pharma in Neoplasms: 3 programs

  1. setidegrasibphase 3
  2. enfortumab vedotinapproved, new study
  3. enzalutamideapproved, new study

Their studies: Astellas Pharma’s studies of Neoplasms in search

AstraZeneca in Neoplasms: 6 programs

  1. saruparibphase 3
  2. ceralasertibphase 3
  3. Leucovorinphase 2
  4. Ramucirumabphase 2
  5. AZD1390phase 1

and 1 more — sign in to see them all

Their studies: AstraZeneca’s studies of Neoplasms in search

Bristol-Myers Squibb in Neoplasms: 5 programs

  1. repotrectinibphase 3
  2. BMS-986488phase 1
  3. BMS-986500phase 1
  4. Digoxinphase 1
  5. relatlimabapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Neoplasms in search

Multiple Myelomaall three · compare here

Astellas Pharma in Multiple Myeloma: 1 program

  1. Methylprednisolonephase 2

Their studies: Astellas Pharma’s studies of Multiple Myeloma in search

Bristol-Myers Squibb in Multiple Myeloma: 6 programs

  1. mezigdomidephase 3
  2. arlocabtagene autoleucelphase 3
  3. Cyclophosphamidephase 2
  4. elranatamabphase 2
  5. fludarabinephase 1

and 1 more — sign in to see them all

Their studies: Bristol-Myers Squibb’s studies of Multiple Myeloma in search

Pulmonary Disease, Chronic Obstructiveall three · compare here

Astellas Pharma in Pulmonary Disease, Chronic Obstructive: 1 program

  1. Prednisolonephase 2

Their studies: Astellas Pharma’s studies of Pulmonary Disease, Chronic Obstructive in search

AstraZeneca in Pulmonary Disease, Chronic Obstructive: 8 programs

  1. tozorakimabphase 3
  2. GP MDIphase 3
  3. AZD6793phase 2
  4. Treatment A: BGF MDI HFOphase 1
  5. tezepelumabapproved, new study

and 3 more — sign in to see them all

Their studies: AstraZeneca’s studies of Pulmonary Disease, Chronic Obstructive in search

Bristol-Myers Squibb in Pulmonary Disease, Chronic Obstructive: 1 program

  1. trospium chlorideapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Pulmonary Disease, Chronic Obstructive in search

Stomach Neoplasmsall three · compare here

Astellas Pharma in Stomach Neoplasms: 1 program

  1. zolbetuximabapproved, new study

Their studies: Astellas Pharma’s studies of Stomach Neoplasms in search

Bristol-Myers Squibb in Stomach Neoplasms: 1 program

  1. relatlimabapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Stomach Neoplasms in search

Arthritis, Rheumatoidall three · compare here

Astellas Pharma in Arthritis, Rheumatoid: 1 program

  1. Prednisolonephase 2

Their studies: Astellas Pharma’s studies of Arthritis, Rheumatoid in search

AstraZeneca in Arthritis, Rheumatoid: 2 programs

  1. surovatamigphase 3
  2. AZD1163phase 2

Their studies: AstraZeneca’s studies of Arthritis, Rheumatoid in search

Bristol-Myers Squibb in Arthritis, Rheumatoid: 3 programs

  1. tocilizumabphase 3
  2. BMS-986528phase 2
  3. BMS-986454phase 1

Their studies: Bristol-Myers Squibb’s studies of Arthritis, Rheumatoid in search

Neoplasm Metastasisall three · compare here

Astellas Pharma in Neoplasm Metastasis: 1 program

  1. enzalutamideapproved, new study

Their studies: Astellas Pharma’s studies of Neoplasm Metastasis in search

AstraZeneca in Neoplasm Metastasis: 3 programs

  1. saruparibphase 3
  2. camizestrantphase 3
  3. trastuzumab deruxtecanapproved, new study

Their studies: AstraZeneca’s studies of Neoplasm Metastasis in search

Bristol-Myers Squibb in Neoplasm Metastasis: 2 programs

  1. adagrasibphase 3
  2. repotrectinibphase 3

Their studies: Bristol-Myers Squibb’s studies of Neoplasm Metastasis in search

Kidney Failure, Chronicall three · compare here

Astellas Pharma in Kidney Failure, Chronic: 1 program

  1. Sirolimusapproved, new study

Their studies: Astellas Pharma’s studies of Kidney Failure, Chronic in search

AstraZeneca in Kidney Failure, Chronic: 1 program

  1. Berzanoflastphase 2

Their studies: AstraZeneca’s studies of Kidney Failure, Chronic in search

Bristol-Myers Squibb in Kidney Failure, Chronic: 3 programs

  1. golcadomidephase 3
  2. admilparantphase 3
  3. mezigdomidephase 3

Their studies: Bristol-Myers Squibb’s studies of Kidney Failure, Chronic in search

Pancreatic Neoplasmsall three · compare here

Astellas Pharma in Pancreatic Neoplasms: 2 programs

  1. setidegrasibphase 3
  2. zolbetuximabapproved, new study

Their studies: Astellas Pharma’s studies of Pancreatic Neoplasms in search

AstraZeneca in Pancreatic Neoplasms: 2 programs

  1. sonesitatug vedotinphase 3
  2. Leucovorinphase 2

Their studies: AstraZeneca’s studies of Pancreatic Neoplasms in search

Bristol-Myers Squibb in Pancreatic Neoplasms: 1 program

  1. navlimetostatphase 3

Their studies: Bristol-Myers Squibb’s studies of Pancreatic Neoplasms in search

Lung Neoplasmsall three · compare here

AstraZeneca in Lung Neoplasms: 1 program

  1. osimertinibapproved, new study

Their studies: AstraZeneca’s studies of Lung Neoplasms in search

Bristol-Myers Squibb in Lung Neoplasms: 1 program

  1. navlimetostatphase 3

Their studies: Bristol-Myers Squibb’s studies of Lung Neoplasms in search

Show all 42

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

TargetAstellas PharmaAstraZenecaBristol-Myers Squibb
CD3Eemaretamigrulesurovatamig, Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492, Anti-Claudin18.2/Anti-CD3 Bispecific Antibody AZD5863, Anti-GPC3 T Cell-engaging Antibody AZD9793, Anti-STEAP2/Anti-CD3/Anti-CD8 Trispecific Antibody AZD6621elranatamabrule
KRASPan-KRAS Degrader ASP5834rulePan-KRAS Inhibitor JAB-23E73, AZD0240adagrasibrule
ARenzalutamideruleAndrogen Receptor Degrader AZD9750ruledezandrodegrule
CD19–Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F, surovatamig, CT204V-CD19 × CD20ruleobexelimab, zolacabtagene autoleucel, lisocabtagene maraleucelrule
CLDN18zolbetuximabrule, emaretamigrule, Anti-Claudin 18.2 Antibody-drug Conjugate ASP546Crulesonesitatug vedotin, Anti-Claudin18.2/Anti-CD3 Bispecific Antibody AZD5863, Anti-Claudin 18.2 Antibody-drug Conjugate AZD4360rule–
PDCD1–rilvegostomig, volrustomigatigotatug, Nivolumabrule
TNFRSF17–Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F, Allogeneic Anti-BCMA CAR T-cells AZD4045tunlucabtagene autoleucel, elranatamabrule
GPRC5D–vemzatatug vedotinarlocabtagene autoleucel, tunlucabtagene autoleucel
NR3C1Methylprednisolonerule, PrednisoloneruleBudesoniderule–
ALKgilteritinibrule–repotrectinibrule
CD274–durvalumabrulepumitamig
EGFR–osimertinibruleizalontamab brengitecan
GPC3–Anti-GPC3 T Cell-engaging Antibody AZD9793Actinium Ac 225 GPC3-targeted Peptide RYZ801
PRMT5–PRMT5 Inhibitor AZD3470navlimetostat
TACSTD2Anti-TROP2/Topoisomerase I Inhibitor-STING Agonist Immunostimulatory ADC ASP2998ruledatopotamab deruxtecanrule–
A target, or a pathogen for a vaccine, known for: Astellas Pharma 12 of 20 · AstraZeneca 68 of 119 · Bristol-Myers Squibb 32 of 57 programs (55 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (AstraZeneca: 5, Bristol-Myers Squibb: 9).